Selected quarterly financial data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2015

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Information

The following table contains quarterly financial information for 2015 and 2014. The Company believes that the following information reflects all normal recurring adjustments necessary for a fair statement of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period.

	2015
	First Quarter			Second Quarter			Third Quarter			Fourth Quarter			Total
	(in thousands, except per share data)
Total revenue	$	6,344		$	4,940		$	1,324		$	1,471		$	14,079
Total operating expenses		31,270			56,963			44,451			50,432			183,116
Loss from operations		(24,926	)		(52,023	)		(43,127	)		(48,961	)		(169,037	)
Net loss		(24,787	)		(51,795	)		(42,924	)		(47,277	)		(166,783	)
Net loss per share applicable to common stockholders - basic    and diluted	$	(0.76	)	$	(1.57	)	$	(1.18	)	$	(1.29	)	$	(4.81	)

	2014
	First Quarter			Second Quarter				Third Quarter			Fourth Quarter			Total
	(in thousands, except per share data)
Total revenue	$	6,335		$	6,335			$	6,365		$	6,386		$	25,421
Total operating expenses		17,003			19,669				23,375			26,000			86,047
Loss from operations		(10,668	)		(13,334	)			(17,010	)		(19,614	)		(60,626	)
Net loss		(10,609	)		(1,526	)	(1)		(17,030	)		(19,544	)		(48,709	)
Net loss per share applicable to common stockholders - basic    and diluted	$	(0.44	)	$	(0.06	)		$	(0.61	)	$	(0.67	)	$	(1.83	)

(1) During the second quarter of 2014, the Company recorded an income tax benefit of $11.8 million in connection with the acquisition of Pregenen completed in June 2014. See Note 11, “Business Combinations” for additional information.